<DOC>
	<DOCNO>NCT02496143</DOCNO>
	<brief_summary>The purpose study determine EC-18 safe tolerable healthy subject .</brief_summary>
	<brief_title>A Safety PK Study EC-18 Healthy Subjects</brief_title>
	<detailed_description>This randomize , double-blind , placebo-controlled study safety , tolerability , PK , pharmacodynamics single ascend dos EC-18 placebo . If dose limit toxicity ( DLT ) observe Cohort One , dose EC-18 increase Cohorts Two , Three , Four , respectively . Dose escalation successive cohort subject occur review safety tolerability data previous cohort complete Investigator , Sponsor , study Medical Monitor together confirm safety tolerability EC-18 give dose level .</detailed_description>
	<mesh_term>Neutropenia</mesh_term>
	<criteria>Females childbearing potential must use acceptable birth control method throughout study 14 day dose study drug . Females nonchildbearing potential ( define surgically sterilize [ tubal ligation/hysterectomy/bilateral salpingooophorectomy ] postmenopausal &gt; 2 year ) negative urine human chorionic gonadotropin pregnancy test Screening Visit . Males willing practice contraception ( condom + spermicide ) study 14 day completion study , female partner use barrier oral contraception timeframe . Body mass index ( BMI ) 18 32 kg/m2 , inclusive . Ability understand give inform consent provide authorization use protect health information ( Health Insurance Portability Accountability Act ) . Willing able confine research clinic require protocol . Febrile ( temperature ≥99.5°F/37.5°C ) Screening Visit admission research clinic Day 1 . Clinically significant laboratory finding Screening Visit define follow : Alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) , bilirubin &gt; 1.5 x upper limit normal ( ULN ) Blood urea nitrogen ( BUN ) , creatinine &gt; 1.25 x ULN White blood cell ( WBC ) count &lt; 0.9 x low limit normal ( LLN ) &gt; 1.1 x ULN Hemoglobin hematocrit &lt; 0.9 x LLN &gt; 1.1 x ULN Platelet count &lt; 0.9 x LLN &gt; 1.1 x ULN Glucose &lt; 0.9 x LLN &gt; 1.25 x ULN Thyroidstimulating hormone ( TSH ) &lt; 0.75 x LLN &gt; 1.25 x ULN laboratory , ECG , vital sign , physical abnormality , investigator 's opinion , unfavorably increase risk study participation . Positivity human immunodeficiency virus ( HIV ) receive active antiretroviral therapy , hepatitis B surface antigen positivity , hepatitis C positivity . History drug alcohol abuse within past 2 year . Females pregnant intend get pregnant next month . Positive urine pregnancy test Screening Visit admission research clinic Day 1 . Positive urine drug breath alcohol test Screening Visit admission research clinic Day 1 . Subjects instructed drink alcohol within 12 hour screen assessment . Intake alcohol within 72 hour prior study drug administration intake grapefruit Seville oranges within 7 day prior administration study drug . Strenuous physical exercise within 48 hour prior study drug administration . Administration overthecounter medication , dietary supplement , vitamin within 7 day prior study drug administration . Excluded list nondaily use acetaminophen dos ≤2 grams 24hour period . Administration prescription drug herbal supplement within 14 day prior study drug administration . .Exposure investigational agent within 30 day prior Screening Visit . Any current medical illness , sign , symptom , investigator 's opinion , could adversely affect subject safety study integrity .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Healthy Volunteers</keyword>
	<keyword>Phase I</keyword>
	<keyword>Placebo control</keyword>
	<keyword>Single Ascending Dose</keyword>
	<keyword>PK</keyword>
	<keyword>Oral administration</keyword>
	<keyword>Softgel</keyword>
</DOC>